Tatva Chintan Pharma Chem Invests Rs 4 Crore in Green Energy Project for Captive Power

2 min read Updated on 18 Feb 2026, 10:20 PM

Reviewed by

Ashish TScanX News Team

Overview

Tatva Chintan Pharma Chem Limited has invested Rs 4,00,00,000 to acquire a 10.99% stake in AMPIN C&I Power Twenty Six Private Limited for renewable energy sourcing. The SPV will develop 9.9 MW solar and wind capacity each in Gujarat, supplying 3.2 MW of both solar and wind power to Tatva Chintan under the Group Captive Power Scheme. This strategic investment aims to reduce energy costs while increasing renewable energy usage in operations.

*this image is generated using AI for illustrative purposes only.

Tatva chintan pharma Chem Limited has disclosed its strategic investment in renewable energy infrastructure through the acquisition of equity shares in AMPIN C&I Power Twenty Six Private Limited. The pharmaceutical company announced this development on 18 February 2026, marking a significant step towards sustainable energy sourcing for its operations.

Investment Structure and Financial Details

The company has entered into multiple agreements to facilitate this green energy acquisition, including a Power Purchase Agreement, Share Purchase and Subscription Agreement, and Option Agreement. The investment involves acquiring 40,00,000 equity shares at Rs 10 per share, representing a total investment of Rs 4,00,00,000.

Investment Parameter:	Details
Total Investment:	Rs 4,00,00,000
Number of Shares:	40,00,000 equity shares
Share Price:	Rs 10 per share
Ownership Stake:	10.99% on fully diluted basis
Investment Mode:	Cash consideration in tranches

Renewable Energy Project Specifications

AMPIN C&I Power Twenty Six Private Limited serves as a Special Purpose Vehicle incorporated specifically for establishing renewable power plants in Gujarat. The project encompasses both solar and wind energy generation capabilities designed for captive consumption under the Group Captive Power Scheme.

Project Specifications:	Capacity
Solar Capacity:	9.9 MW AC
Wind Capacity:	9.9 MW
Solar Power Supply to Tatva Chintan:	3.2 MW
Wind Power Supply to Tatva Chintan:	3.2 MW
Project Location:	Gujarat

Strategic Benefits and Business Impact

This acquisition enables Tatva Chintan to source environment-friendly green energy for long-term captive consumption, supporting the company's sustainability objectives. The arrangement is expected to reduce energy costs significantly while ensuring compliance with Indian electricity laws as a captive user. The investment aligns with the company's commitment to increasing renewable power share in its operations.

Target Entity Background

AMPIN C&I Power Twenty Six Private Limited was incorporated on 17 July 2025 as a subsidiary of AMPIN C&I Power Private Limited. The SPV operates in the renewable energy sector, specifically focusing on wind and solar power generation and transmission for captive consumption. As a recently incorporated entity, the company has not yet commenced business operations.

Regulatory and Completion Timeline

The acquisition does not involve any related party transactions, with no promoter or group company interests in the target entity. The completion timeline depends on obtaining necessary regulatory approvals and consents for open access captive consumption of electricity from relevant authorities. No specific governmental or regulatory approvals are required for the share acquisition itself.

Historical Stock Returns for Tatva Chintan Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.93%	+0.89%	-15.05%	+11.02%	+78.71%	-48.34%

Tatva Chintan Pharma

View Company Insights

View All News

Tatva Chintan Pharma Files SEBI Takeover Disclosure for Promoter Share Transfer

2 min read Updated on 09 Feb 2026, 05:44 PM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Overview

Tatva Chintan Pharma Chem Limited has completed regulatory filings under SEBI Takeover Regulations for the transfer of 7,15,345 equity shares (3.06%) from Ajay Mansukhlal Patel (HUF) to the individual promoter following HUF dissolution. The transaction, executed without monetary consideration, increases the individual promoter's holding from 17.10% to 20.16% while maintaining overall promoter group commitment.

*this image is generated using AI for illustrative purposes only.

Tatva Chintan Pharma Chem Limited has filed a comprehensive disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, following the completion of an inter-se transfer of equity shares between promoter entities. The transaction was executed on 06 February 2026, with formal disclosure submitted to stock exchanges on 09 February 2026.

Transaction Overview

The disclosure pertains to the transfer of 7,15,345 equity shares, representing 3.06% of the company's total issued and paid-up equity share capital. The shares were transferred from Ajay Mansukhlal Patel (HUF) to Ajay Mansukhlal Patel in his individual capacity as promoter, pursuant to the dissolution and full partition of the HUF entity.

Transaction Parameter	Details
Shares Transferred	7,15,345 equity shares
Percentage of Capital	3.06%
Transaction Date	06 February 2026
Transferor	Ajay Mansukhlal Patel (HUF)
Acquirer	Ajay Mansukhlal Patel (Individual)
Consideration	Nil (HUF dissolution and partition)

Regulatory Framework and Exemption

The acquisition was executed under the exemption provided in Regulation 10(1)(a)(ii) of the SEBI Takeover Regulations. Prior intimation under Regulation 10(5) was submitted to the exchanges on 29 January 2026, complying with the prescribed timeline requirements. The transaction qualifies as a family arrangement undertaken for succession planning and rationalization of family assets and business holdings.

Shareholding Pattern Changes

The transfer resulted in significant changes to the promoter shareholding structure while maintaining overall promoter group commitment to the pharmaceutical company.

Entity	Pre-Transaction Holding	Post-Transaction Holding	Change
Ajay Mansukhlal Patel (HUF)	7,15,345 shares (3.06%)	Nil (0.00%)	-7,15,345 shares
Ajay Mansukhlal Patel (Individual)	40,00,000 shares (17.10%)	47,15,345 shares (20.16%)	+7,15,345 shares

Compliance and Documentation

Ajay Mansukhlal Patel, as the promoter and proposed acquirer, submitted the formal disclosure to both BSE Limited (Scrip Code: 543321) and National Stock Exchange of India Limited (Symbol: TATVA). The documentation confirms that no monetary consideration was involved in the transaction, as it formed part of the HUF dissolution process.

Corporate Structure Impact

This internal restructuring consolidates the shareholding under Ajay Mansukhlal Patel's individual ownership while maintaining the overall promoter group's stake in the company. The transfer represents a strategic reorganization of promoter holdings designed for smooth succession planning rather than any change in the fundamental promoter commitment to Tatva Chintan Pharma Chem Limited's operations and growth trajectory.

Historical Stock Returns for Tatva Chintan Pharma